PMID- 36594109
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230505
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 14
IP  - 6
DP  - 2023 Feb
TI  - Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in 
      advanced non-small cell lung cancer: A systematic review and network 
      meta-analysis.
PG  - 535-543
LID - 10.1111/1759-7714.14783 [doi]
AB  - BACKGROUND: The combination of antiangiogenic agents with epidermal growth factor 
      receptor inhibitors (EGFR-TKIs) and chemotherapy with EGFR-TKIs are the most 
      common combination treatment options in epidermal growth factor receptor (EGFR) 
      positive non-small cell lung cancer (NSCLC). This network meta-analysis was 
      performed to evaluate the differences between them. METHODS: We searched the 
      PubMed, EMBASE and the Cochrane Controlled Trials Register up to August 2022. The 
      primary outcomes were progression-free survival (PFS) and objective response rate 
      (ORR). The secondary endpoints were overall survival (OS), disease control rate 
      (DCR) and adverse events (AEs). The data of hazard ratio (HR) or risk ratio (RR) 
      with their corresponding 95% confidence intervals (CIs) were extracted in the 
      studies. A network meta-analysis (NMA) was used to indirectly compare the 
      efficacy and safety of antiangiogenic agents plus EGFR-TKIs and chemotherapy plus 
      EGFR-TKIs. RESULTS: Pooled data of included studies were demonstrated that 
      chemotherapy plus EGFR-TKIs had a benefit in ORR compared to antiangiogenic 
      agents plus EGFR-TKIs in patients with EGFR mutated NSCLC (RR = 1.1, 95% CI: 
      1.0-1.2). However, there were no significant differences in PFS, OS and DCR 
      between in the two group (PFS: HR = 1.0, 95% CI: 0.74-1.6; OS: HR = 0.78, 95% CI: 
      0.45-1.5; DCR: RR = 1.0, 95% CI: 0.94-1.1). The common treatment-related AEs in 
      the two groups were relatively manageable. CONCLUSION: Based on the efficacy and 
      safety, the combination of chemotherapy with EGFR-TKIs is considered the best 
      combination treatment options in advanced NSCLC with EGFR mutation.
CI  - (c) 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Dai, Jiali
AU  - Dai J
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Liu, Xinyin
AU  - Liu X
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Qu, Tianyu
AU  - Qu T
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Cui, Yanan
AU  - Cui Y
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Jin, Shidai
AU  - Jin S
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Zhang, Erbao
AU  - Zhang E
AD  - Department of Epidemiology, Center for Global Health, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 
      Nanjing, China.
FAU - Guo, Renhua
AU  - Guo R
AUID- ORCID: 0000-0003-4475-8617
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20230102
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - *Lung Neoplasms/drug therapy
MH  - *Antineoplastic Agents/therapeutic use
MH  - Network Meta-Analysis
MH  - ErbB Receptors/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
PMC - PMC9968601
OTO - NOTNLM
OT  - antiangiogenic agents
OT  - chemotherapy
OT  - epidermal growth factor receptor inhibitors
OT  - network meta-analysis
OT  - non-small cell lung cancer
COIS- No conflict of interest is declared by the authors.
EDAT- 2023/01/04 06:00
MHDA- 2023/03/03 06:00
PMCR- 2023/01/02
CRDT- 2023/01/03 02:12
PHST- 2022/12/11 00:00 [revised]
PHST- 2022/11/18 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2023/01/04 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/01/03 02:12 [entrez]
PHST- 2023/01/02 00:00 [pmc-release]
AID - TCA14783 [pii]
AID - 10.1111/1759-7714.14783 [doi]
PST - ppublish
SO  - Thorac Cancer. 2023 Feb;14(6):535-543. doi: 10.1111/1759-7714.14783. Epub 2023 
      Jan 2.